What is Acadia Pharmaceuticals Inc's earnings per share (EPS)?

Acadia Pharmaceuticals Inc (ACAD) reported diluted earnings per share of $2.30 for fiscal year 2025. This represents a 69.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acadia Pharmaceuticals Inc Financials

ACAD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Acadia Pharmaceuticals Inc (ACAD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 67/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Acadia Pharmaceuticals Inc has an operating margin of 9.8%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 44/100, indicating healthy but not exceptional operating efficiency. This is down from 24.1% the prior year.

Growth

Acadia Pharmaceuticals Inc's revenue grew 11.9% year-over-year to $1.1B, a solid pace of expansion. This earns a growth score of 53/100.

Leverage

Acadia Pharmaceuticals Inc carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.83, Acadia Pharmaceuticals Inc holds $3.83 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Cash Flow

Acadia Pharmaceuticals Inc has a free cash flow margin of 9.8%, earning a moderate score of 50/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Acadia Pharmaceuticals Inc earns a strong 31.9% return on equity (ROE), meaning it generates $32 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is up from 30.9% the prior year.

Altman Z-Score Safe

6.63

Acadia Pharmaceuticals Inc scores 6.63, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.8B) relative to total liabilities ($336.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Acadia Pharmaceuticals Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.28x

For every $1 of reported earnings, Acadia Pharmaceuticals Inc generates $0.28 in operating cash flow ($109.8M OCF vs $391.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.1B

YoY+11.9%

5Y CAGR+19.4%

10Y CAGR+165.7%

Acadia Pharmaceuticals Inc generated $1.1B in revenue in fiscal year 2025. This represents an increase of 11.9% from the prior year.

EBITDA

$116.6M

YoY-52.7%

Acadia Pharmaceuticals Inc's EBITDA was $116.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.7% from the prior year.

Net Income

$391.0M

YoY+72.7%

Acadia Pharmaceuticals Inc reported $391.0M in net income in fiscal year 2025. This represents an increase of 72.7% from the prior year.

EPS (Diluted)

$2.30

YoY+69.1%

Acadia Pharmaceuticals Inc earned $2.30 per diluted share (EPS) in fiscal year 2025. This represents an increase of 69.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$105.1M

YoY-33.1%

Acadia Pharmaceuticals Inc generated $105.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 33.1% from the prior year.

Cash & Debt

$177.7M

YoY-44.4%

5Y CAGR-11.4%

10Y CAGR+5.7%

Acadia Pharmaceuticals Inc held $177.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

170M

YoY+2.2%

5Y CAGR+1.3%

10Y CAGR+4.2%

Acadia Pharmaceuticals Inc had 170M shares outstanding in fiscal year 2025. This represents an increase of 2.2% from the prior year.

Margins & Returns

Gross Margin

91.7%

YoY+0.2pp

5Y CAGR-6.0pp

Acadia Pharmaceuticals Inc's gross margin was 91.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.2 percentage points from the prior year.

Operating Margin

9.8%

YoY-14.3pp

5Y CAGR+74.7pp

10Y CAGR+269865.5pp

Acadia Pharmaceuticals Inc's operating margin was 9.8% in fiscal year 2025, reflecting core business profitability. This is down 14.3 percentage points from the prior year.

Net Margin

36.5%

YoY+12.8pp

5Y CAGR+100.2pp

10Y CAGR+269615.2pp

Acadia Pharmaceuticals Inc's net profit margin was 36.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 12.8 percentage points from the prior year.

Return on Equity

31.9%

YoY+1.0pp

5Y CAGR+76.8pp

10Y CAGR+114.2pp

Acadia Pharmaceuticals Inc's ROE was 31.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$328.8M

YoY+8.4%

5Y CAGR+0.6%

10Y CAGR+16.1%

Acadia Pharmaceuticals Inc invested $328.8M in research and development in fiscal year 2025. This represents an increase of 8.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.7M

YoY+796.7%

5Y CAGR-9.2%

10Y CAGR+8.2%

Acadia Pharmaceuticals Inc invested $4.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 796.7% from the prior year.

ACAD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.1B+11.9%	$957.8M+31.8%	$726.4M+40.4%	$517.2M+6.8%	$484.1M+9.6%	$441.8M
Cost of Revenue	$89.0M+8.7%	$81.8M+96.6%	$41.6M+309.6%	$10.2M-46.9%	$19.1M+87.5%	$10.2M
Gross Profit	$982.5M+12.2%	$876.0M+27.9%	$684.8M+35.1%	$507.1M+7.1%	$473.3M+9.7%	$431.5M
R&D Expenses	$328.8M+8.4%	$303.2M-13.8%	$351.6M-2.8%	$361.6M+51.0%	$239.4M-25.0%	$319.1M
SG&A Expenses	$548.9M+12.4%	$488.4M+20.1%	$406.6M+10.2%	$369.1M-6.8%	$396.0M+1.9%	$388.7M
Operating Income	$104.8M-54.6%	$230.8M+414.5%	-$73.4M+67.2%	-$223.6M-31.2%	-$170.4M+40.5%	-$286.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$252.1M-897.2%	$31.6M+208.5%	$10.3M+305.0%	$2.5M+621.1%	$351K-42.6%	$611K
Net Income	$391.0M+72.7%	$226.5M+469.5%	-$61.3M+71.6%	-$216.0M-28.7%	-$167.9M+40.4%	-$281.6M
EPS (Diluted)	$2.30+69.1%	$1.36+467.6%	$-0.37+72.4%	$-1.34-27.6%	$-1.05+41.3%	$-1.79

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$284.0M+1.9%	$278.6M+5.3%	$264.6M+8.3%	$244.3M-5.9%	$259.6M+3.7%	$250.4M+3.5%	$242.0M+17.6%	$205.8M
Cost of Revenue	$26.2M+21.1%	$21.6M+4.4%	$20.7M+1.7%	$20.4M-6.5%	$21.8M+15.6%	$18.9M+3.4%	$18.2M-20.6%	$23.0M
Gross Profit	$257.8M+0.3%	$257.0M+5.4%	$243.8M+8.9%	$223.9M-5.8%	$237.8M+2.7%	$231.5M+3.5%	$223.7M+22.3%	$182.9M
R&D Expenses	$84.8M-3.5%	$87.8M+12.7%	$78.0M-0.4%	$78.3M-22.3%	$100.7M+51.2%	$66.6M-12.6%	$76.2M+27.7%	$59.7M
SG&A Expenses	$155.6M+16.7%	$133.4M-0.1%	$133.5M+5.6%	$126.4M-2.9%	$130.1M-2.4%	$133.3M+13.9%	$117.1M+8.4%	$108.0M
Operating Income	$17.4M-51.4%	$35.8M+10.4%	$32.4M+67.8%	$19.3M-87.4%	$153.5M+385.1%	$31.6M+4.0%	$30.4M+100.1%	$15.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$247.2M-809.5%	-$27.2M-300.7%	$13.5M+54.1%	$8.8M-49.3%	$17.3M+187.1%	$6.0M+59.3%	$3.8M-14.7%	$4.4M
Net Income	$273.6M+281.1%	$71.8M+169.2%	$26.7M+40.4%	$19.0M-86.8%	$143.7M+338.7%	$32.8M-1.9%	$33.4M+101.7%	$16.6M
EPS (Diluted)	N/A	$0.42+162.5%	$0.16+45.5%	$0.11	N/A	$0.200.0%	$0.20+100.0%	$0.10

ACAD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.6B+31.7%	$1.2B+58.6%	$749.0M+27.4%	$587.8M-16.0%	$700.1M-10.5%	$782.6M
Current Assets	$1.1B+13.2%	$938.3M+52.3%	$616.1M+21.3%	$507.9M-17.8%	$617.8M-13.9%	$717.6M
Cash & Equivalents	$177.7M-44.4%	$319.6M+69.4%	$188.7M+64.3%	$114.8M-22.1%	$147.4M-54.8%	$326.0M
Inventory	$111.4M+21.5%	$91.7M+126.7%	$40.4M+249.9%	$11.6M-18.0%	$14.1M+45.6%	$9.7M
Accounts Receivable	$121.5M+23.0%	$98.7M+0.5%	$98.3M+58.0%	$62.2M-3.4%	$64.4M+33.4%	$48.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$336.8M-26.0%	$455.0M+43.4%	$317.2M+69.3%	$187.4M+17.7%	$159.2M+2.3%	$155.6M
Current Liabilities	$277.1M-29.8%	$394.9M+55.3%	$254.3M+102.4%	$125.6M+30.8%	$96.1M-9.3%	$106.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.2B+67.5%	$732.8M+69.7%	$431.8M+7.8%	$400.4M-26.0%	$540.9M-13.7%	$627.0M
Retained Earnings	-$1.8B+17.7%	-$2.2B+9.3%	-$2.4B-2.6%	-$2.4B-10.0%	-$2.2B-8.5%	-$2.0B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.6B+17.5%	$1.3B+8.6%	$1.2B+8.2%	$1.1B-4.7%	$1.2B+21.6%	$976.9M+6.9%	$914.1M+6.9%	$855.1M
Current Assets	$1.1B-1.3%	$1.1B+12.1%	$960.6M+10.3%	$870.9M-7.2%	$938.3M+19.0%	$788.3M+8.1%	$728.9M+7.9%	$675.3M
Cash & Equivalents	$177.7M-31.1%	$258.0M+1.7%	$253.6M+16.5%	$217.7M-31.9%	$319.6M+106.0%	$155.1M-12.4%	$177.1M-13.5%	$204.7M
Inventory	$111.4M+5.1%	$106.0M-4.1%	$110.5M+7.3%	$103.0M+12.3%	$91.7M+5.7%	$86.7M+0.8%	$86.1M+29.1%	$66.6M
Accounts Receivable	$121.5M+4.8%	$115.8M+7.8%	$107.5M+1.7%	$105.7M+7.1%	$98.7M+0.5%	$98.2M-5.3%	$103.7M+9.5%	$94.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$336.8M-18.5%	$413.5M+2.6%	$403.2M+9.8%	$367.1M-19.3%	$455.0M+13.8%	$399.7M+0.6%	$397.4M+1.6%	$391.1M
Current Liabilities	$277.1M-22.3%	$356.6M+8.0%	$330.0M+9.1%	$302.5M-23.4%	$394.9M+14.8%	$343.9M+1.8%	$337.9M+2.2%	$330.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.2B+33.8%	$917.3M+11.5%	$822.4M+7.5%	$765.2M+4.4%	$732.8M+27.0%	$577.2M+11.7%	$516.7M+11.3%	$464.0M
Retained Earnings	-$1.8B+13.1%	-$2.1B+3.3%	-$2.2B+1.2%	-$2.2B+0.9%	-$2.2B+6.1%	-$2.3B+1.4%	-$2.4B+1.4%	-$2.4B

ACAD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$109.8M-30.4%	$157.7M+844.3%	$16.7M+114.6%	-$114.0M+9.3%	-$125.7M+7.7%	-$136.2M
Capital Expenditures	$4.7M+796.7%	$523K+946.0%	$50K	$0-100.0%	$1.1M-85.2%	$7.6M
Free Cash Flow	$105.1M-33.1%	$157.2M+844.0%	$16.7M+114.6%	-$114.0M+10.1%	-$126.8M+11.8%	-$143.8M
Investing Cash Flow	-$302.6M-890.8%	-$30.5M-195.4%	$32.0M-56.3%	$73.2M+203.0%	-$71.1M-136.9%	$192.5M
Financing Cash Flow	$49.9M+628.8%	$6.8M-72.8%	$25.1M+206.5%	$8.2M-54.9%	$18.2M-77.6%	$81.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$48.7M-165.6%	$74.3M+16.2%	$64.0M+214.7%	$20.3M-49.7%	$40.4M-36.2%	$63.2M+152.9%	$25.0M-14.0%	$29.1M
Capital Expenditures	$4.0M+932.2%	$388K	N/A	N/A	$453K+547.1%	$70K	N/A	N/A
Free Cash Flow	-$52.7M-171.4%	$73.9M	N/A	N/A	$39.9M-36.8%	$63.2M	N/A	N/A
Investing Cash Flow	-$55.9M+29.6%	-$79.4M-83.3%	-$43.3M+65.1%	-$124.0M-201.6%	$122.2M+248.1%	-$82.5M-46.7%	-$56.2M-300.3%	-$14.0M
Financing Cash Flow	$22.7M+140.5%	$9.4M-40.9%	$16.0M+768.1%	$1.8M-6.7%	$2.0M+634.7%	$268K-92.5%	$3.6M+241.8%	$1.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACAD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	91.7%+0.2pp	91.5%-2.8pp	94.3%-3.8pp	98.0%+0.3pp	97.8%+0.1pp	97.7%
Operating Margin	9.8%-14.3pp	24.1%+34.2pp	-10.1%+33.1pp	-43.2%-8.0pp	-35.2%+29.7pp	-64.9%
Net Margin	36.5%+12.8pp	23.6%+32.1pp	-8.4%+33.3pp	-41.8%-7.1pp	-34.7%+29.1pp	-63.7%
Return on Equity	31.9%+1.0pp	30.9%+45.1pp	-14.2%+39.8pp	-53.9%-22.9pp	-31.0%+13.9pp	-44.9%
Return on Assets	25.0%+5.9pp	19.1%+27.3pp	-8.2%+28.6pp	-36.7%-12.8pp	-24.0%+12.0pp	-36.0%
Current Ratio	3.83+1.5	2.38-0.0	2.42-1.6	4.04-2.4	6.43-0.3	6.77
Debt-to-Equity	0.27-0.3	0.62-0.1	0.73+0.3	0.47+0.2	0.29+0.0	0.25
FCF Margin	9.8%-6.6pp	16.4%+14.1pp	2.3%+24.3pp	-22.1%+4.1pp	-26.2%+6.3pp	-32.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	90.8%-1.5pp	92.2%+0.1pp	92.2%+0.5pp	91.6%+0.0pp	91.6%-0.9pp	92.5%0.0pp	92.5%+3.6pp	88.8%
Operating Margin	6.1%-6.7pp	12.8%+0.6pp	12.2%+4.3pp	7.9%-51.2pp	59.1%+46.5pp	12.6%+0.1pp	12.6%+5.2pp	7.4%
Net Margin	96.3%+70.6pp	25.8%+15.7pp	10.1%+2.3pp	7.8%-47.6pp	55.4%+42.3pp	13.1%-0.7pp	13.8%+5.8pp	8.0%
Return on Equity	22.3%+14.5pp	7.8%+4.6pp	3.2%+0.8pp	2.5%-17.1pp	19.6%+13.9pp	5.7%-0.8pp	6.5%+2.9pp	3.6%
Return on Assets	17.5%+12.1pp	5.4%+3.2pp	2.2%+0.5pp	1.7%-10.4pp	12.1%+8.8pp	3.4%-0.3pp	3.6%+1.7pp	1.9%
Current Ratio	3.83+0.8	3.02+0.1	2.91+0.0	2.88+0.5	2.38+0.1	2.29+0.1	2.16+0.1	2.04
Debt-to-Equity	0.27-0.2	0.45-0.0	0.49+0.0	0.48-0.1	0.62-0.1	0.69-0.1	0.77-0.1	0.84
FCF Margin	-18.6%-45.1pp	26.5%	N/A	N/A	15.4%-9.9pp	25.2%	N/A	N/A

Similar Companies

$7.4B

$6.7B

$8.4B

$7.6B

Arrowhead Pharma ARWR

$8.5B

Frequently Asked Questions

What is Acadia Pharmaceuticals Inc's annual revenue?

Acadia Pharmaceuticals Inc (ACAD) reported $1.1B in total revenue for fiscal year 2025. This represents a 11.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Acadia Pharmaceuticals Inc's revenue growing?

Acadia Pharmaceuticals Inc (ACAD) revenue grew by 11.9% year-over-year, from $957.8M to $1.1B in fiscal year 2025.

Is Acadia Pharmaceuticals Inc profitable?

Yes, Acadia Pharmaceuticals Inc (ACAD) reported a net income of $391.0M in fiscal year 2025, with a net profit margin of 36.5%.

What is Acadia Pharmaceuticals Inc's EBITDA?

Acadia Pharmaceuticals Inc (ACAD) had EBITDA of $116.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Acadia Pharmaceuticals Inc's gross margin?

Acadia Pharmaceuticals Inc (ACAD) had a gross margin of 91.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Acadia Pharmaceuticals Inc's operating margin?

Acadia Pharmaceuticals Inc (ACAD) had an operating margin of 9.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Acadia Pharmaceuticals Inc's net profit margin?

Acadia Pharmaceuticals Inc (ACAD) had a net profit margin of 36.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Acadia Pharmaceuticals Inc's return on equity (ROE)?

Acadia Pharmaceuticals Inc (ACAD) has a return on equity of 31.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Acadia Pharmaceuticals Inc's free cash flow?

Acadia Pharmaceuticals Inc (ACAD) generated $105.1M in free cash flow during fiscal year 2025. This represents a -33.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Acadia Pharmaceuticals Inc's operating cash flow?

Acadia Pharmaceuticals Inc (ACAD) generated $109.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Acadia Pharmaceuticals Inc's total assets?

Acadia Pharmaceuticals Inc (ACAD) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Acadia Pharmaceuticals Inc's capital expenditures?

Acadia Pharmaceuticals Inc (ACAD) invested $4.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Acadia Pharmaceuticals Inc spend on research and development?

Acadia Pharmaceuticals Inc (ACAD) invested $328.8M in research and development during fiscal year 2025.

How many shares does Acadia Pharmaceuticals Inc have outstanding?

Acadia Pharmaceuticals Inc (ACAD) had 170M shares outstanding as of fiscal year 2025.

What is Acadia Pharmaceuticals Inc's current ratio?

Acadia Pharmaceuticals Inc (ACAD) had a current ratio of 3.83 as of fiscal year 2025, which is generally considered healthy.

What is Acadia Pharmaceuticals Inc's debt-to-equity ratio?

Acadia Pharmaceuticals Inc (ACAD) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Acadia Pharmaceuticals Inc's return on assets (ROA)?

Acadia Pharmaceuticals Inc (ACAD) had a return on assets of 25.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Acadia Pharmaceuticals Inc's Altman Z-Score?

Acadia Pharmaceuticals Inc (ACAD) has an Altman Z-Score of 6.63, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Acadia Pharmaceuticals Inc's Piotroski F-Score?

Acadia Pharmaceuticals Inc (ACAD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Acadia Pharmaceuticals Inc's earnings high quality?

Acadia Pharmaceuticals Inc (ACAD) has an earnings quality ratio of 0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Acadia Pharmaceuticals Inc?

Acadia Pharmaceuticals Inc (ACAD) scores 67 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.